| Autor: |
Songpeng, Yang, Shu, Yang, Hongying, Zhang, Hui, Hua, Qingbin, Kong, Jiao, Wang, Yangfu, Jiang |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
British journal of pharmacologyREFERENCES. 178(21) |
| ISSN: |
1476-5381 |
| Popis: |
The multikinase inhibitor sorafenib is a first-line drug for advanced hepatocellular carcinoma. The response to sorafenib varies among hepatocellular carcinoma patients and many of the responders suffer from reduced sensitivity after long-term treatment. This study aims to explore a novel strategy to potentiate or maximize the anti-hepatocellular carcinoma effects of sorafenib.We used hepatocellular carcinoma cell lines, western blotting, various antagonists, siRNA and tumour xenografts mouse model to determine the anti- hepatocellular carcinoma effects of sorafenib in combination with berbamine or other NaBerbamine and the cardiotonic steroid, ouabain, synergize with sorafenib to inhibit hepatocellular carcinoma cells growth. Mechanistically, berbamine induces Src phosphorylation in NaBerbamine or other Na |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
